GLP-1 Agonists Increase Lung Mucus Production and May Worsen Obstructive Lung Disease
Exendin-4 and liraglutide increased mucin production in airways via p38 signaling, worsening emphysematous features — cautioning against inhaled GLP-1 drugs in patients with obstructive lung diseases.
Quick Facts
What This Study Found
GLP-1 receptor agonists upregulate mucin expression in airways via p38 MAPK, exacerbating emphysematous phenotypes in obstructive lung disease models.
Key Numbers
Exendin-4 and liraglutide upregulated mucin; p38 MAPK activation; worsened emphysema in obstructive model; GLP-1R highly expressed in lung
How They Did This
Combined in-vitro (airway epithelial cells) and in-vivo (mouse) studies testing exendin-4 and liraglutide effects on mucin expression and pulmonary pathology under normal and obstructive conditions.
Why This Research Matters
Millions of people use GLP-1 drugs for diabetes and obesity. If these drugs worsen lung disease, patients with concurrent COPD or asthma need careful monitoring — especially as inhaled GLP-1 delivery is explored.
The Bigger Picture
This study reveals an unexpected adverse effect of GLP-1 signaling in the lungs, adding nuance to the otherwise positive therapeutic profile of GLP-1 receptor agonists.
What This Study Doesn't Tell Us
Mouse and cell culture models — human relevance not confirmed; intratracheal delivery may produce higher local concentrations than systemic administration; short-term study.
Questions This Raises
- ?Do systemic GLP-1 agonists (subcutaneous injection) also increase lung mucus production in patients?
- ?Are COPD patients on GLP-1 drugs at higher risk for exacerbations?
- ?Could p38 inhibitors mitigate the pulmonary side effects of GLP-1 therapy?
Trust & Context
- Key Stat:
- Mucus increase + worse emphysema GLP-1 agonists upregulated mucin via p38 and exacerbated obstructive lung disease phenotypes in mice
- Evidence Grade:
- Consistent findings across in-vitro and in-vivo models with mechanistic pathway identification, but limited to animal models without clinical confirmation.
- Study Age:
- Published in 2020; with GLP-1 agonist use expanding dramatically, pulmonary effects warrant clinical investigation.
- Original Title:
- Intratracheal GLP-1 receptor agonist treatment up-regulates mucin via p38 and exacerbates emphysematous phenotype in mucus hypersecretory obstructive lung diseases.
- Published In:
- Biochemical and biophysical research communications, 524(2), 332-339 (2020)
- Authors:
- Nohara, Hirofumi, Nakashima, Ryunosuke, Kamei, Shunsuke, Fujikawa, Haruka, Ueno-Shuto, Keiko, Kawakami, Taisei, Eto, Yuka, Suico, Mary Ann, Li, Jian-Dong, Kai, Hirofumi, Shuto, Tsuyoshi
- Database ID:
- RPEP-05037
Evidence Hierarchy
Frequently Asked Questions
Can GLP-1 drugs affect the lungs?
Yes — this study found GLP-1 agonists stimulate mucus production in airways and can worsen obstructive lung disease in mice, raising concerns for patients with COPD or asthma.
Should people with lung disease avoid GLP-1 drugs?
This animal study raises a concern, but clinical evidence in humans is still needed. Patients with obstructive lung disease using GLP-1 drugs should discuss any respiratory symptoms with their doctor.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-05037APA
Nohara, Hirofumi; Nakashima, Ryunosuke; Kamei, Shunsuke; Fujikawa, Haruka; Ueno-Shuto, Keiko; Kawakami, Taisei; Eto, Yuka; Suico, Mary Ann; Li, Jian-Dong; Kai, Hirofumi; Shuto, Tsuyoshi. (2020). Intratracheal GLP-1 receptor agonist treatment up-regulates mucin via p38 and exacerbates emphysematous phenotype in mucus hypersecretory obstructive lung diseases.. Biochemical and biophysical research communications, 524(2), 332-339. https://doi.org/10.1016/j.bbrc.2020.01.081
MLA
Nohara, Hirofumi, et al. "Intratracheal GLP-1 receptor agonist treatment up-regulates mucin via p38 and exacerbates emphysematous phenotype in mucus hypersecretory obstructive lung diseases.." Biochemical and biophysical research communications, 2020. https://doi.org/10.1016/j.bbrc.2020.01.081
RethinkPeptides
RethinkPeptides Research Database. "Intratracheal GLP-1 receptor agonist treatment up-regulates ..." RPEP-05037. Retrieved from https://rethinkpeptides.com/research/nohara-2020-intratracheal-glp1-receptor-agonist
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.